New JDRF Call: Safe and Effective Use of SGLT Inhibitors for Type 1 Diabetes

The Juvenile Diabetes Research Foundation (JDRF) has issued a Request for Applications for innovative research to advance safe, effective use of SGLT inhibitors for Type 1 diabetes (T1D). Funding of up to US$400,000 over two years is available for academic, industrial and joint academic/industrial projects that will deliver findings that can be translated into increased safe and effective use of SGLT inhibitors for T1D in the near- and middle-term.

JDRF is committed to improving outcomes in people with T1D through the use of adjunctive drugs that complement insulin therapy. Drugs in the sodium-glucose linked transporter inhibitor class (i.e. SGLT2 and SGLT1/2 inhibitors) have demonstrated efficacy in T1D. However, clinical trials have shown an increased risk of diabetic ketoacidosis (DKA) in people with T1D taking these drugs at the most efficacious doses.

While several SGLT inhibitors are approved for T1D in Europe and Japan as insulin adjuncts, none are yet approved for T1D in the United States. JDRF recognises the potential benefits of SGLT inhibitors for T1D and the urgent need to mitigate their associated risk of DKA to support the successful use of these effective therapies in T1D worldwide.

Examples of research appropriate for this RFA include but are not limited to:

Development and testing of education/safety/monitoring tools or protocols to prevent DKA

Physiology studies to better understand ketosis and DKA

Development of pharmacological or other interventions to prevent DKA

Development and/or testing of novel and user-friendly ketone monitoring technologies

Assessment of real world efficacy and safety outcomes for SGLT inhibitors in T1D

Data analysis to determine T1D patient characteristics (demographic, clinical, biological, behavioural, T1D management regimen, other) that predict efficacy and/or safety of SGLT inhibitors

Additional analysis of data from pivotal phase 3 clinical studies

Applications may be submitted by domestic and foreign non-profit organisations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments and, where applicable, eligible agencies of the federal government. Applicants must hold a faculty position or equivalent at a college, university, medical school, industry setting or other research facility. There are no citizenship requirements.

Proposals may be submitted under the JDRF Strategic Research Agreement (SRA) and Industry Discovery & Development Partnership (IDDP) funding mechanisms.

Letters of Intent should be submitted by the deadline of 28 October 2019.

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.